PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright

by · The Cerbat Gem

PDS Biotechnology (NASDAQ:PDSB – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $21.00 target price on the stock.

A number of other research analysts have also recently weighed in on PDSB. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.25.

Check Out Our Latest Report on PDSB

PDS Biotechnology Price Performance

PDS Biotechnology stock traded down $0.23 during trading hours on Friday, hitting $2.02. The stock had a trading volume of 614,474 shares, compared to its average volume of 615,880. PDS Biotechnology has a 1-year low of $1.53 and a 1-year high of $6.85. The stock has a market capitalization of $74.38 million, a price-to-earnings ratio of -1.66 and a beta of 1.93. The stock’s fifty day moving average is $3.23 and its two-hundred day moving average is $3.27. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84.

PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the company earned ($0.37) EPS. As a group, analysts predict that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Tempus Wealth Planning LLC purchased a new position in PDS Biotechnology during the second quarter worth approximately $55,000. Ground Swell Capital LLC acquired a new position in PDS Biotechnology in the second quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in PDS Biotechnology during the second quarter valued at about $115,000. Squarepoint Ops LLC acquired a new stake in PDS Biotechnology during the second quarter worth about $120,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of PDS Biotechnology in the 2nd quarter worth about $146,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

(Get Free Report)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

Further Reading